GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (FRA:CLM) » Definitions » Degree of Operating Leverage

Clearside Biomedical (FRA:CLM) Degree of Operating Leverage : 0.38 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Clearside Biomedical Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Clearside Biomedical's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 0.38. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Clearside Biomedical's Degree of Operating Leverage or its related term are showing as below:

FRA:CLM's Degree of Operating Leverage is ranked worse than
59.32% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs FRA:CLM: 0.38

Clearside Biomedical Degree of Operating Leverage Historical Data

The historical data trend for Clearside Biomedical's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Degree of Operating Leverage Chart

Clearside Biomedical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.35 -48.71 -0.04 -0.08

Clearside Biomedical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.04 -0.08 -0.08 0.38

Competitive Comparison of Clearside Biomedical's Degree of Operating Leverage

For the Biotechnology subindustry, Clearside Biomedical's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Degree of Operating Leverage falls into.


;
;

Clearside Biomedical Degree of Operating Leverage Calculation

Clearside Biomedical's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -18.58 (Mar. 2025) / -23.467 (Mar. 2024) - 1 )/( 3.466 (Mar. 2025) / 7.775 (Mar. 2024) - 1 )
=-0.2082/-0.5542
=0.38***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Clearside Biomedical  (FRA:CLM) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Clearside Biomedical Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearside Biomedical Business Description

Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical Headlines

From GuruFocus

Cornerstone Funds Announce Continuing Monthly Distributions

By Marketwired Marketwired 05-07-2021

Cornerstone Total Return Fund, Inc. Announces Rights Offering

By GuruFocusNews GuruFocusNews 04-08-2022

Cornerstone Funds Announce Continuing Monthly Distributions

By GuruFocusNews GuruFocusNews 06-12-2022

Cornerstone Funds Announce Continuing Monthly Distributions

By GuruFocusNews GuruFocusNews 07-02-2022

Cornerstone Funds File Their Annual Reports

By GuruFocusNews GuruFocusNews 03-02-2022

Cornerstone Strategic Value Fund Inc's Dividend Analysis

By GuruFocus Research 10-12-2023

Cornerstone Funds Announce Continuing Monthly Distributions

By GuruFocusNews GuruFocusNews 05-13-2022

Cornerstone Funds File Their Annual Reports

By Marketwired Marketwired 02-29-2020